CL2021002889A1 - Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis - Google Patents

Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis

Info

Publication number
CL2021002889A1
CL2021002889A1 CL2021002889A CL2021002889A CL2021002889A1 CL 2021002889 A1 CL2021002889 A1 CL 2021002889A1 CL 2021002889 A CL2021002889 A CL 2021002889A CL 2021002889 A CL2021002889 A CL 2021002889A CL 2021002889 A1 CL2021002889 A1 CL 2021002889A1
Authority
CL
Chile
Prior art keywords
treatment
t1dm
antibodies
insulitis
therapies
Prior art date
Application number
CL2021002889A
Other languages
English (en)
Inventor
Pascal Espie
Allison Goldfine
Rainer Mussmann
James Rush
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021002889A1 publication Critical patent/CL2021002889A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La divulgación se refiere a métodos, regímenes de tratamiento, usos, equipos y terapias para el tratamiento de T1DM, empleando anticuerpos anti–CD40
CL2021002889A 2019-05-08 2021-11-03 Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis CL2021002889A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962844960P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
CL2021002889A1 true CL2021002889A1 (es) 2022-08-12

Family

ID=70680549

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002889A CL2021002889A1 (es) 2019-05-08 2021-11-03 Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis

Country Status (13)

Country Link
US (1) US20220195061A1 (es)
EP (1) EP3966240A1 (es)
JP (2) JP2021518854A (es)
KR (1) KR20220007086A (es)
CN (1) CN113784985A (es)
AU (1) AU2020267953A1 (es)
BR (1) BR112021021923A2 (es)
CA (1) CA3137682A1 (es)
CL (1) CL2021002889A1 (es)
IL (1) IL287464A (es)
MX (1) MX2021013631A (es)
TW (1) TW202108617A (es)
WO (1) WO2020225736A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
PL1889065T3 (pl) * 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
SI3178851T1 (sl) 2010-03-31 2020-09-30 Boehringer Inhelheim International Gmbh Anti-CD40 protitelesa
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
MX2018002708A (es) * 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
CA3094600A1 (en) * 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection

Also Published As

Publication number Publication date
AU2020267953A1 (en) 2021-11-18
IL287464A (en) 2021-12-01
TW202108617A (zh) 2021-03-01
JP2021518854A (ja) 2021-08-05
JP2022116272A (ja) 2022-08-09
EP3966240A1 (en) 2022-03-16
BR112021021923A2 (pt) 2022-02-22
CN113784985A (zh) 2021-12-10
US20220195061A1 (en) 2022-06-23
CA3137682A1 (en) 2020-11-12
MX2021013631A (es) 2022-04-12
KR20220007086A (ko) 2022-01-18
WO2020225736A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CO2017008804A2 (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017001994A2 (es) Compuestos activos hacia bromodominios
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
BR112017007003A2 (pt) método para modulação de atividade de células imunes induzidas por car
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
PH12016502574A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
ECSP20029790A (es) Compuestos moduladores de sting y métodos de elaboración y uso
DK3880676T3 (da) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-on-derivater som hpk1-inhibitorer til behandling af cancer
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
TW201713333A (en) Methods of treating a neurodegenerative disease
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
CL2021000744A1 (es) Métodos para tratar trastornos mieloproliferativos
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CL2020003348A1 (es) Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa